Significantly, (pro) renin receptor (PRR), a new biomarker for different types of cancer such as colorectal cancer, breast cancer, glioma, aldosterone-producing adenoma, urothelial cancer, and pancreatic ductal adenocarcinoma, has also been regarded as a potential prognostic and therapeutic biomarker for endometrial cancer (8). This evidence concerns the gene ATP6AP2 and cancer.